BRCA1 and pachyonychia congenita: Indeed, BRCA1/2 mutations are responsible for a group of hereditary PCs; specific drugs (poly-ADP ribose polymerase inhibitors, PARPi) can be administered to BRCA-mutated PC patients, according to the NCCN guidelines [4,9,19,23,53,56,92].